← Back to Screener
Protara Therapeutics, Inc. Common Stock (TARA)
Price$5.30
Favorite Metrics
Price vs S&P 500 (26W)-4.53%
Price vs S&P 500 (4W)-5.08%
Market Capitalization$294.22M
All Metrics
Book Value / Share (Quarterly)$3.67
P/TBV (Annual)0.13x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.05
Price vs S&P 500 (YTD)-2.07%
EPS (TTM)$-1.34
10-Day Avg Trading Volume0.52M
EPS Excl Extra (TTM)$-1.34
EPS (Annual)$-1.34
ROI (Annual)-29.24%
Cash / Share (Quarterly)$2.90
ROA (Last FY)-27.42%
EBITD / Share (TTM)$-1.48
ROE (5Y Avg)-41.77%
Cash Flow / Share (Annual)$-1.05
P/B Ratio1.50x
P/B Ratio (Quarterly)1.40x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-3.02x
ROA (TTM)-33.81%
EPS Incl Extra (Annual)$-1.34
Current Ratio (Annual)14.58x
Quick Ratio (Quarterly)14.34x
3-Month Avg Trading Volume0.99M
52-Week Price Return36.00%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$6.77
P/S Ratio (Annual)99.74x
Asset Turnover (Annual)0.03x
52-Week High$7.82
EPS Excl Extra (Annual)$-1.34
CapEx CAGR (5Y)-36.07%
Tangible BV CAGR (5Y)24.06%
26-Week Price Return4.21%
Quick Ratio (Annual)14.34x
13-Week Price Return10.12%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)14.58x
Enterprise Value$244.562
Book Value / Share Growth (5Y)-27.09%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-113.22%
Cash / Share (Annual)$2.90
3-Month Return Std Dev84.09%
Net Income / Employee (TTM)$-1
ROE (Last FY)-29.24%
Net Interest Coverage (Annual)-4.75x
EPS Basic Excl Extra (Annual)$-1.34
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.34
ROI (TTM)-36.38%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$9.06
Price vs S&P 500 (52W)0.91%
Year-to-Date Return2.06%
5-Day Price Return7.30%
EPS Normalized (Annual)$-1.34
ROA (5Y Avg)-37.76%
Net Profit Margin (Annual)-113.22%
Month-to-Date Return4.41%
Cash Flow / Share (TTM)$-6.09
EBITD / Share (Annual)$-1.48
Operating Margin (Annual)-256.95%
ROI (5Y Avg)-41.77%
EPS Basic Excl Extra (TTM)$-1.34
P/TBV (Quarterly)0.18x
P/B Ratio (Annual)1.40x
Book Value / Share (Annual)$3.67
Price vs S&P 500 (13W)7.26%
Beta1.58x
Revenue / Share (TTM)$0.00
ROE (TTM)-36.38%
52-Week Low$2.77
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.17
4.15
4.15
4.14
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
TARAProtara Therapeutics, Inc. Common Stock | — | — | — | — | $5.30 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Protara Therapeutics develops transformative therapies for cancer and rare diseases with limited treatment options. The pipeline includes TARA-002 for lymphatic malformations and intravenous choline chloride for intestinal failure-associated liver disease (IFALD). The company focuses on underserved patient populations with significant unmet medical needs.